Formerly Biopharmaceutical Research Company

Live.

Every.

Day.

BRC is working to develop safe, non-addictive medicines to address pain and other conditions.

BRC Therapeutics (BRC) is a pharmaceutical company focused on developing proprietary cannabinoid therapeutics to address unmet medical needs.

BRC’s medicines are multimodal and contain major and minor cannabinoids at defined ratios. BRC has developed a pipeline of treatments addressing pain and neurological and inflammatory conditions. Two investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA), respectively. BRC is registered with the Drug Enforcement Administration.

Our therapeutics are multimodal by design

We are combining major and minor cannabinoids at ratios that are narrowly defined and predicted to maximize safety and efficacy. Our medicines are designed to ensure each patient's comfort and support their return to a life not dictated by their symptoms.

Our team consists of leaders in the pharmaceutical and regulated cannabinoid therapeutics industries. We are building a fully integrated organization, driving innovation from development to commercialization

“BRC is a mission-driven company with excellent leadership in a high growth industry, a business that is already in a significantly advantageous position given their unique ability to be fully compliant with the DEA.”

– Howard Goodwin, MD, Managing Partner,
Intrinsic Capital Partners

patient & doctor

Ongoing Clinical Trials in CRPS and AIIA

Two of our therapeutic candidates are currently being tested in investigator-initiated clinical trials for Complex Regional Pain Syndrome and Aromatase Inhibitor-Induced Arthralgia.

14 May 2025
Stephen Wright, MD, Joins BRC Therapeutics as Development Advisor
» Full release
25 January 2025
BRC Announces Development and Regulatory Milestone Following Successful Type C CMC Meeting with FDA, Advancing Clinical Development of Multiple Therapeutic Candidates
» Full release
3 December 2024
BRC-002 receives Orphan Drug Designation from FDA for Complex Regional Pain Syndrome
» Full release

More than symptom relief

At BRC, we recognize that everyone deserves to live a life not dictated by their symptoms. We have dedicated ourselves to help patients Live Every Day to the fullest.